Scientists are now testing a new drug that does something Ozempic and GLP-1 drugs can't. It targets fat while protecting muscle.

Scientists are now testing a new drug that does something Ozempic and GLP-1 drugs can't. It targets fat while protecting muscle. And it's a pill, not a shot. The drug is called ATR-258. Ozempic and other GLP-1 drugs work by changing hunger signals between your gut and brain. ATR-258 works in a different way. It ignores hunger. It targets your muscle instead, so your muscles burn more energy and handle blood sugar better. ATR-258 still needs larger Phase II trials. So this is early. But the idea is huge. The obesity drug market is headed toward $100B by 2030.